|
Sep 30
|
Is Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?
|
|
Jul 29
|
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy
|
|
Jul 25
|
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Jun 26
|
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
|
|
Jun 12
|
Grant of Restricted Stock Units and Warrants to Employees in Genmab
|
|
Jun 1
|
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
|
|
May 23
|
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 22
|
Genmab acquires biotechnology company ProfoundBio in $1.8bn deal
|
|
May 21
|
Genmab Completes Acquisition of ProfoundBio
|
|
May 15
|
Market Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
|
|
May 14
|
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
|
|
May 14
|
Danish biotech says companies should tap into China’s ‘impressive innovation’
|
|
May 3
|
Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript
|
|
May 2
|
Genmab Announces Financial Results for the First Quarter of 2024
|
|
May 1
|
Comstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...
|
|
Apr 30
|
Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer
|
|
Apr 29
|
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
|
|
Apr 29
|
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
|
|
Apr 16
|
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
|
|
Apr 15
|
Roche reports survival data for new dual-acting lymphoma drug
|